Eliana Clark - Feb 23, 2022 Form 3 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Signature
/s/ James Basta, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Feb 23, 2022
Transactions value $
$0
Form type
3
Date filed
3/7/2022, 06:15 PM
Next filing
Mar 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NTLA Common Stock 5.64K Feb 23, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NTLA Stock Option (right to buy) Feb 23, 2022 Common Stock 62.8K $12.27 Direct F2
holding NTLA Stock Option (right to buy) Feb 23, 2022 Common Stock 31.5K $57.71 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes a grant of 5,250 restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2 This option was granted on February 3, 2020 with respect to 75,000 shares of Common Stock, with 25% vesting on January 6, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
F3 This option was granted on March 3, 2021 with respect to 31,500 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter.